Cognition Therapeutics(US:CGTX) Globenewswireยท2025-11-06 12:30Core Insights - Cognition Therapeutics, Inc. has completed a $30 million registered direct offering to support the next stage of development for its drug zervimesine (CT1812) [2][8] - The company has aligned with the U.S. FDA on a registrational path for zervimesine in Alzheimer's disease, which is seen as a significant achievement [2][8] - An ongoing expanded access program for zervimesine in dementia with Lewy bodies is in place [8] Financial Highlights - As of September 30, 2025, the company reported cash, cash equivalents, and restricted cash equivalents of approximately $39.8 million, with total obligated grant funds remaining from the National Institute of Aging at $36.3 million [4] - Research and development expenses for Q3 2025 were $3.8 million, a decrease from $11.4 million in Q3 2024, attributed to the completion of clinical trials [5] - General and administrative expenses were $2.6 million for Q3 2025, down from $3.1 million in Q3 2024, primarily due to reduced stock-based compensation [6] - The net loss for Q3 2025 was $4.9 million, or $(0.06) per share, compared to a net loss of $9.9 million, or $(0.25) per share, for the same period in 2024 [6][11] Business Developments - The company has surpassed 75% enrollment in the Phase 2 'START' study of zervimesine in early Alzheimer's disease, which is being conducted in collaboration with the Alzheimer's Clinical Trials Consortium [8] - Clinical pharmacology and bioavailability studies are being executed to prepare zervimesine for the next stage of development across various indications [8] - The proposed registrational study design for Alzheimer's disease has been accepted for presentation at the Clinical Trials in Alzheimer's Disease (CTAD) Conference scheduled for December 1-4, 2025 [8]